ArticleBreast cancer (Tokyo, Japan)2021
Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
Article in Breast cancer (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06360809 (Prehabilitation Exercise Program in Breast Cancer), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prehabilitation Exercise Program in Breast Cancer: Effects on Quality of Life and Tumor Microenvironment (PEP_BC)
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping to estimate health state utility: a systematic review of development and limitations.Health and quality of life outcomes · 2025Pooled it
- Utility score mapping from FACT-G to EQ-5D-5L and SF-6Dv2 in breast and colorectal cancer patients: a focus on beta mixture models.Health and quality of life outcomes · 2025Article
- Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China.Health and quality of life outcomes · 2023Article
- Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.Frontiers in public health · 2023Article
- Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.Frontiers in endocrinology · 2023Article
- Determination of a cost-effectiveness threshold for cancer interventions in Iran.Frontiers in oncology · 2022Article
- Distributional health and financial consequences of increased cigarette tax in Iran: extended cost-effectiveness analysis.Health economics review · 2021Article
- Interim value set for the EQ-5D-5L in Iran using the Crosswalk method.Medical journal of the Islamic Republic of Iran · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe health-related quality of life (HRQoL) data extracted from cancer-specific questionnaires are often non-preference based, while patient preference-based utility data are required for health economic evaluation. This study aimed to map Functional Assessment of Cancer Therapy-Breast (FACT-B) subscales onto the Short Form six Dimension as an independent instrument (SF-6Dv2
methodsData for 420 inpatient and outpatient patients with breast cancer were gathered from the largest academic center for cancer patients in Iran. The OLS and Tobit models were used to predict the values of the SF-6Dv2
resultsData of 416 patients with breast cancer were entered into final analysis. The model included main effects of FACT-B subscales, and statistically significant clinical and demographic variables were the best predictor for SF-6Dv2
conclusionThe best algorithm developed for SF-6Dv2
Indexed as
Identifiers
32712768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.